Compare PCB & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCB | BNTC |
|---|---|---|
| Founded | 2003 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 410.1M | 454.2M |
| IPO Year | 2018 | 2020 |
| Metric | PCB | BNTC |
|---|---|---|
| Price | $28.09 | $12.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $25.50 | ★ $27.67 |
| AVG Volume (30 Days) | 41.1K | ★ 69.8K |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | 48.28 | ★ 80.94 |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $2,899,000.00 | N/A |
| Revenue This Year | $13.73 | N/A |
| Revenue Next Year | $9.07 | N/A |
| P/E Ratio | $38.01 | ★ N/A |
| Revenue Growth | ★ 4.51 | N/A |
| 52 Week Low | $19.70 | $9.85 |
| 52 Week High | $30.84 | $16.76 |
| Indicator | PCB | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 49.03 | 51.71 |
| Support Level | $27.31 | $11.35 |
| Resistance Level | $29.29 | $13.48 |
| Average True Range (ATR) | 0.94 | 0.70 |
| MACD | -0.22 | 0.01 |
| Stochastic Oscillator | 22.78 | 56.15 |
PCB Bancorp is a bank holding company, which engages in the provision of consumer and commercial banking services. It provides Personal, Business, and Loan services, which provide banking, lending, and digital, tools, home loans, and others. Also, it offers a broad range of loans, deposits, and other products and services predominantly to small and middle-market businesses and individuals. The company provided it's services in Los Angeles and Orange Counties, California; Bellevue, Washington; and Atlanta, Georgia.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.